Zobrazeno 51 - 60
of 84
pro vyhledávání: '"329"'
Autor:
Xavier Thomas, Nicolini Franck-Emmanuel, Mohamed El Hamri, Fiorenza Barraco, Véronique Lhéritier, Maël Heiblig, Sophie Ducastelle-Lepretre, Hélène Labussière, Eric Wattel, Mauricette Michallet
Publikováno v:
Blood. 124:3679-3679
Obesity is associated with an increased risk of mortality from cardiovascular causes and from malignancies while meta-analyses have evidenced a significant association between an elevated body mass index (BMI) and the risk to develop certain hematolo
Autor:
Jason Gotlib, Caramazza Domenica, Lisa Pieri, Tiziano Barbui, Timothy Devos, Paola Guglielmelli, Giorgina Specchia, Elisa Rumi, Margherita Maffioli, Mario Cazzola, Kiladjian Jean Jacques, Nicola Vianelli, Richard T. Silver, Rami S. Komrokji, Umberto Vitolo, Rambaldi Alessandro, Vannucchi Alessandro, Morra Enrica, Cristiana Pascutto, Valerio De Stefano, Barbara Mora, Cervantes Francisco, Francesco Passamonti, Marco Ruggeri
Publikováno v:
Blood. 124:1826-1826
Background. Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms that can progress to secondary myelofibrosis (MF), named post-PV (PPV) MF and post-ET (PET) MF. While outcome of primary myelofibrosis is d
Autor:
Kimberly B. Dahlman, Megan L. Hames, Mahsa S. Talbott, Judy P. Tsai, Wade T. Iams, Nishitha Reddy, Kristy L. Richards
Publikováno v:
Blood. 124:4438-4438
Background: The use of lenalidomide is expanding to include patients with refractory or relapsed diffuse large B cell lymphoma (DLBCL). Lenalidomide is less toxic than thalidomide, but it leads to hypothyroidism in approximately 5-10% of patients tha
Autor:
Pieter Sonneveld, Chrissy H. Y. Van Beurden-Tan, Philippe Moreau, Laura Rosiñol, Walter M Gregory, Michel van Agthoven
Publikováno v:
Blood. 124:2122-2122
INTRODUCTION Multiple Myeloma (MM) is an incurable disease and its treatment is characterized by treatment sequences (treatment lines). We questioned whether a health economic (HE) model could be developed that analyses treatment sequences (TS) rathe
Publikováno v:
Blood. 124:4856-4856
Background: Health services and outcomes research in sickle cell disease (SCD) has been limited by inadequate population-based surveillance and reliance on ICD-9 codes to identify individuals with SCD. The accuracy of ICD-9 coding in administrative c
Publikováno v:
Blood. 124:1852-1852
Background: PV is a myeloproliferative neoplasm characterized by increased red cell mass and elevated hematocrit. Phlebotomy represents the initial treatment option to lower hematocrit with the goal of reducing the risk of thrombosis. However, many p
Autor:
Wolfgang Kern, Karolína Perglerová, Susanne Schnittger, Manja Meggendorfer, Tamara Alpermann, Claudia Haferlach, Torsten Haferlach, Niroshan Nadarajah
Publikováno v:
Web of Science
Background: NPM1 mutations (mut) are considered the most frequent mutations in de novo acute myeloid leukemia (AML) and have been suggested as provisional entity in the WHO classification 2008. It has become clear that nearly all NPM1mut AML have add
Autor:
Markus Loeffler, Norbert Schmitz, Randy D. Gascoyne, Roopesh Kansara, Michael Pfreundschuh, Bertram Glass, Samira Zeynalova, Kerry J. Savage, David Scott, Diego Villa, Laurie H. Sehn, Joseph M. Connors, Maike Nickelsen, Marita Ziepert
Publikováno v:
Blood. 124:394-394
[Graphic][1] Introduction : Despite the improvement of outcome of aggressive B-cell lymphomas in the rituximab treatment era, central nervous system (CNS) relapse continues to pose a significant management problem. It remains a challenge to select pa
Autor:
Georg Mann, Dieter Printz, Gertraud Fröschl, Ulrike Pötschger, Gerhard Fritsch, Michael Dworzak, Helmut Gadner, Nora Mühlegger
Publikováno v:
Blood. 99(6)
Detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) predicts outcome. Previous studies were invariably based on relative quantification and did not investigate sample-inherent parameters that influence test accuracy, whi
Autor:
Torsten Haferlach, Susanne Schnittger, Wolfgang Kern, Tamara Alpermann, Claudia Haferlach, Sabine Jeromin
Publikováno v:
Blood. 122:2776-2776
Background SF3B1 mutations (SF3B1mut) correlate with the presence of ring sideroblasts (RS) and can be found in MDS and in AML. Aim To evaluate the incidence of SF3B1mut in a large cohort of MDS and AML patients (pts) with ≥15% RS, and furthermore